
Absci Corp (ABSI) Stock Forecast & Price Target
Absci Corp (ABSI) Analyst Ratings
Bulls say
Absci Corp's integration of biologic drug discovery and cell line development positions it uniquely in the therapeutic market, enhancing efficiency and innovation in the creation of novel biologics. A strong clinical activity signal for ABS-101 is projected to increase the probability of success in ulcerative colitis and Crohn's disease, which is pivotal for attracting interest from larger pharmaceutical companies. The anticipated positive readout is expected to validate Absci's broader platform, suggesting an implied potential upside of approximately 30% compared to the base case.
Bears say
Absci Corp faces a negative outlook primarily due to increased dilution arising from recent financing activities, which significantly impacts its valuation. The consistent lowering of the price target to $8 indicates concerns regarding the company's financial health and its ability to maintain shareholder value amid this dilution. Overall, the repeated reference to a diminished price target suggests a cautious approach to Absci’s stock performance moving forward.
This aggregate rating is based on analysts' research of Absci Corp and is not a guaranteed prediction by Public.com or investment advice.
Absci Corp (ABSI) Analyst Forecast & Price Prediction
Start investing in Absci Corp (ABSI)
Order type
Buy in
Order amount
Est. shares
0 shares